JOP20220039A1 - صيغ ثابتة لمضاد حيوي من ببتيد سكري - Google Patents
صيغ ثابتة لمضاد حيوي من ببتيد سكريInfo
- Publication number
- JOP20220039A1 JOP20220039A1 JOP/2022/0039A JOP20220039A JOP20220039A1 JO P20220039 A1 JOP20220039 A1 JO P20220039A1 JO P20220039 A JOP20220039 A JO P20220039A JO P20220039 A1 JOP20220039 A1 JO P20220039A1
- Authority
- JO
- Jordan
- Prior art keywords
- glycopeptide antibiotic
- antibiotic formulations
- formulations
- stabilized glycopeptide
- stabilized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
يتعلق الاختراع الحالي بصيغ سائلة من مضادات حيوية من ببتيد سكري أو أملاح مقبولة صيدلانيًا منه، حيث يتم اختيار المضاد الحيوي من الببتيد السكري من فانكوميسين، تيلافانسين، أوريتافانسين، تيكوبلانين ودالبافانسين. الصيغ المذكورة تكون مناسبة كمحاليل تسريب أو كناتج تركيز لعمل محاليل تسريب.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662333357P | 2016-05-09 | 2016-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20220039A1 true JOP20220039A1 (ar) | 2023-01-30 |
Family
ID=58745200
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2017/0111A JOP20170111B1 (ar) | 2016-05-09 | 2017-05-07 | صيغ ثابتة لمضاد حيوي من ببتيد سكري |
JOP/2022/0039A JOP20220039A1 (ar) | 2016-05-09 | 2022-02-17 | صيغ ثابتة لمضاد حيوي من ببتيد سكري |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2017/0111A JOP20170111B1 (ar) | 2016-05-09 | 2017-05-07 | صيغ ثابتة لمضاد حيوي من ببتيد سكري |
Country Status (20)
Country | Link |
---|---|
US (1) | US10729708B2 (ar) |
EP (1) | EP3454883A1 (ar) |
JP (1) | JP6946343B2 (ar) |
KR (1) | KR20190005940A (ar) |
CN (1) | CN109069580A (ar) |
AR (1) | AR109454A1 (ar) |
AU (1) | AU2017262943B2 (ar) |
BR (1) | BR112018072948A2 (ar) |
CA (1) | CA3021935A1 (ar) |
CL (1) | CL2018003147A1 (ar) |
CO (1) | CO2018011701A2 (ar) |
EA (1) | EA201892413A1 (ar) |
IL (1) | IL262796A (ar) |
JO (2) | JOP20170111B1 (ar) |
MX (1) | MX2018013584A (ar) |
SA (1) | SA518400392B1 (ar) |
SG (1) | SG11201809908TA (ar) |
TW (2) | TWI769694B (ar) |
UY (1) | UY37233A (ar) |
WO (1) | WO2017194385A1 (ar) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ731955A (en) | 2014-11-06 | 2023-07-28 | Xellia Pharmaceuticals Aps | Glycopeptide compositions |
US20210346288A1 (en) * | 2020-05-11 | 2021-11-11 | Cai Gu Huang | Pharmaceutical formulation containing active metabolites of remdesivir for inhalation |
EP4014969A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
EP4014965A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
CN115804832A (zh) * | 2021-09-14 | 2023-03-17 | 海南普利制药股份有限公司 | 一种万古霉素水溶液组合物 |
WO2023171588A1 (ja) * | 2022-03-08 | 2023-09-14 | 国立大学法人大阪大学 | 抗菌薬を含有するplga製剤 |
WO2023211501A1 (en) * | 2022-04-26 | 2023-11-02 | Hikma Pharmaceuticals Usa Inc. | Stable, ready-to-administer aqueous formulations of dalbavancin |
GB202207345D0 (en) | 2022-05-19 | 2022-07-06 | Arecor Ltd | Novel composition |
GB202207344D0 (en) | 2022-05-19 | 2022-07-06 | Arecor Ltd | Novel composition |
CN117618338A (zh) * | 2022-08-16 | 2024-03-01 | 海南普利制药股份有限公司 | 一种稳定的奥利万星药物水溶液及其制备方法 |
WO2024079224A1 (en) * | 2022-10-12 | 2024-04-18 | Xellia Pharmaceuticals Aps | Liquid dalbavancin composition |
WO2024079223A1 (en) * | 2022-10-12 | 2024-04-18 | Xellia Pharmaceuticals Aps | Liquid dalbavancin composition |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1278549A (en) * | 1916-12-16 | 1918-09-10 | J E Simmons | Nut and bolt lock. |
US4670258A (en) | 1984-02-10 | 1987-06-02 | Vanderbilt University | Storable prepackaged aqueous solutions of vancomycin |
US4885275A (en) | 1987-10-15 | 1989-12-05 | Eli Lilly And Company | Vancomycin-HCL solutions and the lyophilization thereof |
AU1407197A (en) | 1995-12-01 | 1997-06-19 | Eli Lilly And Company | Stable vancomycin hydrochloride solutions |
JPH1180021A (ja) | 1997-09-02 | 1999-03-23 | Kayaku:Kk | バンコマイシン注射剤 |
AU2001259306A1 (en) * | 2000-05-02 | 2001-11-12 | Advanced Medicine, Inc. | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
EP1276759B1 (en) * | 2000-05-02 | 2008-07-30 | Theravance, Inc. | Reductive alkylation process on glycopeptides |
AU2001259298A1 (en) * | 2000-05-02 | 2001-11-12 | Advanced Medicine, Inc. | Polyacid glycopeptide derivatives |
AU6701101A (en) * | 2000-06-21 | 2002-01-02 | Cubist Pharm Inc | Compositions and methods to improve the oral absorption of antimicrobial agents |
UA75083C2 (uk) * | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
US7119061B2 (en) * | 2002-11-18 | 2006-10-10 | Vicuron Pharmaceuticals, Inc. | Dalbavancin compositions for treatment of bacterial infections |
CA2543443A1 (en) | 2003-10-31 | 2005-05-12 | The University Of Kansas | Sulfoalkyl ether-alkyl ether cyclodextrin derivatives |
US7960337B2 (en) | 2005-02-14 | 2011-06-14 | Venues Remedies Limited | Parenteral combination therapy for infective conditions with drug resistant bacterium |
CN1857716A (zh) * | 2006-03-14 | 2006-11-08 | 浙江大学 | 注射用盐酸万古霉素及其制备方法 |
JP2008201778A (ja) | 2007-01-25 | 2008-09-04 | Mochida Pharmaceut Co Ltd | バンコマイシン液状製剤 |
WO2009036121A1 (en) | 2007-09-12 | 2009-03-19 | Targanta Therapeutics Corp. | Method of inhibiting clostridium difficile by administration of oritavancin |
US7635773B2 (en) * | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
CN102755629A (zh) * | 2012-08-02 | 2012-10-31 | 上海瑞创医药科技有限公司 | 与万古霉素形成抗菌增效包合物的组分和制备方法及其应用 |
EP3581186A1 (en) * | 2012-11-29 | 2019-12-18 | Insmed Incorporated | Stabilized vancomycin formulations |
CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
WO2014194296A1 (en) | 2013-05-30 | 2014-12-04 | Scidose, Llc | Formulations of vancomycin |
NZ731955A (en) * | 2014-11-06 | 2023-07-28 | Xellia Pharmaceuticals Aps | Glycopeptide compositions |
EA036750B1 (ru) | 2016-01-08 | 2020-12-16 | Гуфик Байосайенсиз Лимитед | Лиофилизированная парентеральная композиция тигециклина и способ ее приготовления |
BR112018016715A2 (pt) * | 2016-02-18 | 2019-02-19 | Melinta Therapeutics, Inc. | ?formulações de oritavancina? |
-
2017
- 2017-05-04 CA CA3021935A patent/CA3021935A1/en active Pending
- 2017-05-04 JP JP2018558750A patent/JP6946343B2/ja active Active
- 2017-05-04 EA EA201892413A patent/EA201892413A1/ru unknown
- 2017-05-04 SG SG11201809908TA patent/SG11201809908TA/en unknown
- 2017-05-04 EP EP17724773.1A patent/EP3454883A1/en not_active Withdrawn
- 2017-05-04 KR KR1020187035449A patent/KR20190005940A/ko not_active Application Discontinuation
- 2017-05-04 WO PCT/EP2017/060653 patent/WO2017194385A1/en unknown
- 2017-05-04 MX MX2018013584A patent/MX2018013584A/es unknown
- 2017-05-04 AU AU2017262943A patent/AU2017262943B2/en not_active Ceased
- 2017-05-04 CN CN201780027315.7A patent/CN109069580A/zh active Pending
- 2017-05-04 BR BR112018072948-5A patent/BR112018072948A2/pt not_active IP Right Cessation
- 2017-05-04 US US16/300,137 patent/US10729708B2/en active Active
- 2017-05-07 JO JOP/2017/0111A patent/JOP20170111B1/ar active
- 2017-05-08 UY UY0001037233A patent/UY37233A/es active IP Right Grant
- 2017-05-08 AR ARP170101197A patent/AR109454A1/es unknown
- 2017-05-09 TW TW110104598A patent/TWI769694B/zh active
- 2017-05-09 TW TW106115255A patent/TWI772296B/zh active
-
2018
- 2018-10-29 CO CONC2018/0011701A patent/CO2018011701A2/es unknown
- 2018-11-05 IL IL262796A patent/IL262796A/en unknown
- 2018-11-06 CL CL2018003147A patent/CL2018003147A1/es unknown
- 2018-11-07 SA SA518400392A patent/SA518400392B1/ar unknown
-
2022
- 2022-02-17 JO JOP/2022/0039A patent/JOP20220039A1/ar unknown
Also Published As
Publication number | Publication date |
---|---|
CA3021935A1 (en) | 2017-11-16 |
AR109454A1 (es) | 2018-12-12 |
AU2017262943A1 (en) | 2018-11-22 |
UY37233A (es) | 2018-01-02 |
MX2018013584A (es) | 2019-04-01 |
CN109069580A (zh) | 2018-12-21 |
WO2017194385A1 (en) | 2017-11-16 |
US10729708B2 (en) | 2020-08-04 |
SG11201809908TA (en) | 2018-12-28 |
TWI772296B (zh) | 2022-08-01 |
CL2018003147A1 (es) | 2018-12-28 |
EA201892413A1 (ru) | 2019-05-31 |
BR112018072948A2 (pt) | 2019-02-19 |
TW201740955A (zh) | 2017-12-01 |
SA518400392B1 (ar) | 2022-05-09 |
JOP20170111B1 (ar) | 2022-03-14 |
JP6946343B2 (ja) | 2021-10-06 |
US20190175632A1 (en) | 2019-06-13 |
CO2018011701A2 (es) | 2019-02-08 |
JP2019518733A (ja) | 2019-07-04 |
AU2017262943B2 (en) | 2020-05-14 |
EP3454883A1 (en) | 2019-03-20 |
KR20190005940A (ko) | 2019-01-16 |
TWI769694B (zh) | 2022-07-01 |
IL262796A (en) | 2018-12-31 |
TW202133875A (zh) | 2021-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20220039A1 (ar) | صيغ ثابتة لمضاد حيوي من ببتيد سكري | |
EP3813715A4 (en) | SYSTEMS AND METHODS FOR CONCOMITANT MEDICAL INTERVENTIONS | |
EP4282489A3 (en) | Treatment of clostridium difficile infection | |
EP3856065A4 (en) | Robotic systems and methods for concomitant endoscopic and percutaneous medical procedures | |
MX2022000056A (es) | Peptidos anti-microbianos estabilizados. | |
EP3749190A4 (en) | SYSTEM AND METHOD OF INTERFACING WITH A BIOLOGICAL FABRIC | |
EP3576598A4 (en) | SYSTEMS AND PROCEDURES FOR REGISTRATION FOR IMAGE-GUIDED PROCEDURES | |
EP3576663A4 (en) | IMAGE GUIDED PROCEDURE RECORDING SYSTEMS AND METHODS | |
EP3934519A4 (en) | SURGICAL RECORDING SYSTEMS AND METHODS | |
EP3578639A4 (en) | MEANS TO ACCELERATE THE GROWTH OF STEM CELLS WITH DIFFERENTIATION POTENTIAL | |
EP3576653A4 (en) | SYSTEM AND PROCEDURE FOR DELIVERY AND POSITIONING OF SURGICAL IMPLANTS | |
EP3731846A4 (en) | DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF INFECTIONS | |
EP3544666A4 (en) | BODY LIGHT DEVIATION SYSTEM AND METHOD | |
EP3903745A4 (en) | DELIVERY SYSTEM FOR A MEDICAL IMPLANT | |
MX2021007524A (es) | Analogos de rifamicina y conjugados de farmaco-anticuerpo de los mismos. | |
EP3545916A4 (en) | MEDICAL INTERVENTION INSTRUMENT DELIVERY SYSTEM | |
GB201906653D0 (en) | Polypeptides for treatment of bacterial infections | |
EP3865140A4 (en) | PREVENTATIVE AND/OR THERAPEUTIC AGENT FOR CLOSTRIDIUM DIFFICILE INFECTION | |
EP3706729A4 (en) | FUSOGENIC COMPOUNDS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | |
EP3801703A4 (en) | IN-FABRIC DRUG DELIVERY SYSTEM | |
EP4004180A4 (en) | SCALABLE BIOREACTOR SYSTEMS AND TISSUE GROWING METHODS | |
EP3592349A4 (en) | ADMINISTRATION OF ANTIBIOTIC COMPOUNDS FOR THE TREATMENT OF STREPTOCOCCAL INFECTIONS, FOR THE TREATMENT OF PSORIASIS | |
MX2021002909A (es) | Vacunas de proteinas de fusion neumococicas. | |
EP3863609A4 (en) | SMALL POLYMERIC CARRIERS FOR DELIVERY OF ACTIVE INGREDIENTS | |
WO2014176068A3 (en) | Treatment and prevention of bacterial skin infections using oritavancin |